Medivation rejects Sanofi again

Source: mdvn's marriage on July 7, 2016 has become one of the hottest topics in the pharmaceutical industry recently After Sanofi's $9.3 billion purchase price was rejected two months ago, several companies including Pfizer, Amgen and celgene have expressed their hope to acquire mdvn Mdvn announced yesterday that it would present internal information to Sanofi Some observers thought it was a friendly change of attitude towards Sanofi, but the CVR of Sanofi $58 / share plus $3 / share (the additional acquisition fee that may be given according to the future performance of its PARP inhibitor) was still rejected by mdvn Mdvn also reportedly allows Pfizer and segene to access their internal information in order to reach an acquisition agreement Mdvn's number one product is the prostate cancer drug xtandi, with a peak sales forecast of $5.7 billion (shared with partner Astra) Mdvn has recently become more popular thanks to advances in PARP inhibitors When Sanofi offered $9.3 billion two months ago, the field was not as hot as it is now But after the positive effect of niraparib, the PARP inhibitor of Tessaro, on ovarian cancer, not only the market value of Tessaro doubled, but also the value of talazoparib, a similar drug of mdvn, soared The biopharmaceutical market is changing rapidly Although the PARP activity of talazoparib is only 15 times that of niraparib, PARP trapping (the function of attaching PARP to DNA strand) is 50 times that of niraparib Unsurprisingly, medivation believes that PARP trapping is a better predictor of clinical efficacy Today, mdvn held a conference call with investors to announce that talazoparib may be listed in the market of ovarian cancer, lung cancer, breast cancer, prostate cancer and other diseases with a total value of about 30 billion US dollars, but mdvn did not give peak sales Most analysts think this estimate is a bit optimistic about talazoparib, which will be the fourth or fifth PARP inhibitor to be launched Mdvn not only steps on several ships and negotiates with many big pharmaceutical companies at the same time, but also exports Sanofi, the most enthusiastic one It is said that Sanofi's bid is so low because they don't understand the value of tumor drugs or the development of tumor drugs It started with Sanofi's own PARP project Sanofi used to be the most leading enterprise in the field of PARP, but its PARP inhibitor was later proved by several research groups not to be a PARP inhibitor, which was rather embarrassing Ironically, this kind of Oolong also happened to mdvn recently The PD-1 antibody pidilizumab they bought from curetech did not block PD-1, so they stopped clinical trials of the drug The high value of tumor drugs and the insufficient supply of the product lines of large pharmaceutical factories have created a situation that mdvn is loved by everyone High quality projects are indeed being sought after by the market now From this perspective, it is a good time for technological capital to enter the biopharmaceutical industry Some experts predict that the purchase price of mdvn may be around $70 per share, and some even estimate that it will reach $100 per share, with a market value of $20 billion We'll see how much the final deal is